Dipyridamole with low-dose aspirin augments the infarct size-limiting effects of simvastatin

Cardiovascular Drugs and Therapy

Volumn 24, Issue 5-6, 2010, Pages 391-399

  Ye, Yumei ^a   Long, Bo ^a   Qian, Jinqiao ^a,b   Perez Polo, Jose R ^a   Birnbaum, Yochai ^a,c,d  

^a University of Texas Medical Branch School of Medicine   (United States)

^b KUNMING MEDICAL UNIVERSITY   (China)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Adenosine; Aspirin; Dipyridamole; Reperfusion injury; Statins

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DIPYRIDAMOLE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SIMVASTATIN;

ACUTE DRUG ADMINISTRATION; ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HEART INFARCTION SIZE; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ASPIRIN; CREB-BINDING PROTEIN; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE TYPE III; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN;

EID: 79958699276     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-010-6252-x     Document Type: Article

References (33)

1. Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;4:39-46. (Pubitemid 13078094)
2. Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc Drugs Ther. 2005;19:357-63. (Pubitemid 43029821)
3. Ali Raza J, Reeves WC, Movahed A. Pharmacological stress agents for evaluation of ischemic heart disease. Int J Cardiol. 2001;81:157-67. (Pubitemid 34017434)
4. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238-51.
5. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Intracoronary administration of dipyridamole prior to percutaneous transluminal coronary angioplasty provides a protective effect exceeding that of ischemic preconditioning. Coron Artery Dis. 2000;11:607-13.
6. Heintzen MP, Heidland UE, Klimek WJ, et al. Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial. Heart 2000;83:551-6. (Pubitemid 30316721)
7. Heidland UE, Heintzen MP, Michel CJ, Strauer BE. Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial. Am Heart J. 2000;139:1039-45. (Pubitemid 30390333)
8. Yoshida Y, Hirai M, Yamada T, et al. Antiarrhythmic efficacy of dipyridamole in treatment of reperfusion arrhythmias: evidence for cAMP-mediated triggered activity as a mechanism responsible for reperfusion arrhythmias. Circulation 2000;101:624-30. (Pubitemid 30094733)
9. Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 1991;83:1534-42.
10. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1-211.
11. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008;51:210-47.
12. Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-41.
13. Ye Y, Lin Y, Perez-Polo R, et al. Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination. Am J Physiol Heart Circ Physiol. 2007;293:H813-8.
14. Sanada S, Asanuma H, Minamino T, et al. Optimal windows of statin use for immediate infarct limitation: 5?-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 2004;110:2143-9. (Pubitemid 39372492)
15. Merla R, Ye Y, Lin Y, et al. The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. Am J Physiol Heart Circ Physiol. 2007;293:H1918-28.
16. Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol. 2006;290:H1960-8.
17. Birnbaum Y, Ye Y, Rosanio S, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemiareperfusion injury. Cardiovasc Res. 2005;65:345-55. (Pubitemid 40082476)
18. Birnbaum Y, Lin Y, Ye Y, et al. Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin. Am J Physiol Heart Circ Physiol. 2007;292:H2891-7.
19. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal. 2003;15:813-27. (Pubitemid 36776656)
20. Inserte J, Garcia-Dorado D, Ruiz-Meana M, et al. Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism. Cardiovasc Res. 2004;64:105-14. (Pubitemid 39208927)
21. Sanada S, Asanuma H, Tsukamoto O, et al. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004;110:51-7. (Pubitemid 38880133)
22. Marais E, Genade S, Lochner A. CREB activation and ischaemic preconditioning. Cardiovasc Drugs Ther. 2008;22:3-17.
23. Nagy N, Shiroto K, Malik G, et al. Ischemic preconditioning involves dual cardio-protective axes with p38MAPK as upstream target. J Mol Cell Cardiol. 2007;42:981-90. (Pubitemid 46678032)
24. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999;68:821-61. (Pubitemid 29449210)
25. Kwak HJ, Park KM, Choi HE, et al. PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal. 2008;20: 803-14.
26. Das S, Tosaki A, Bagchi D, Maulik N, Das DK. Resveratrol-mediated activation of cAMP response element-binding protein through adenosine A3 receptor by Akt-dependent and -independent pathways. J Pharmacol Exp Ther. 2005;314:762-9. (Pubitemid 41043860)
27. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol. 1999;151:65-77.
28. Li B, Kaetzel MA, Dedman JR. Signaling pathways regulating murine cardiac CREB phosphorylation. Biochem Biophys Res Commun. 2006;350:179-84. (Pubitemid 44466589)
29. Ozgen N, Obreztchikova M, Guo J, et al. Protein kinase D links Gq-coupled receptors to cAMP response element-binding protein (CREB)-Ser133 phosphorylation in the heart. J Biol Chem. 2008;283:17009-19.
30. Eliseev RA, Vanwinkle B, Rosier RN, Gunter TE. Diazoxide-mediated preconditioning against apoptosis involves activation of cAMP-response element-binding protein (CREB) and NFkappaB. J Biol Chem. 2004;279:46748-54. (Pubitemid 39518323)
31. Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost. 2009;101:626-34.
32. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med. 2005;15:69-75. (Pubitemid 40693390)
33. Ye Y, Martinez JD, Perez-Polo RJ, et al. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase- 2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol. 2008;295:H343-51.